http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
TG Therapeutics publishes data showing BRIUMVI reduced MS relapses by 56.7%
-
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
-
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
TG Therapeutics reports positive phase 3 trial for simplified BRIUMVI dosing
-
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
-
TG Therapeutics presents BRIUMVI data at multiple sclerosis meeting
-
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
-
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
-
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
-
TG Therapeutics presents BRIUMVI data at neurology meeting
-
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
-
TG Therapeutics completes enrollment for subcutaneous BRIUMVI trial
-
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
-
TG Therapeutics secures $500 million credit facility, expands buyback
-
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
-
TG Therapeutics data shows BRIUMVI reduces relapse rates in active MS patients
-
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
-
TG Therapeutics to present BRIUMVI data at neurology meeting
-
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
-
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
-
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
-
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
-
TG Therapeutics presents BRIUMVI data at multiple sclerosis forum
-
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
-
TG Therapeutics to present BRIUMVI data at multiple sclerosis conference
-
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
-
TG Therapeutics reports $616M 2025 revenue, targets $875-900M for 2026
-
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
-
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
-
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
-
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
-
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
-
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
-
TG Therapeutics completes enrollment for BRIUMVI dosing trial
-
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
-
TG Therapeutics reports six-year BRIUMVI data at ECTRIMS conference
-
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
-
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
-
TG Therapeutics begins phase 3 trial for subcutaneous BRIUMVI
-
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
-
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
-
TG Therapeutics completes $100 million buyback, authorizes new program
-
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
-
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
-
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
-
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
-
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
-
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
TG Therapeutics (TGTX) Announces Data Presentations for BRIUMVI
